Chimeric IgG1 monoclonal antibody targeting EGFR; blocks ligand binding to inhibit downstream signaling (RAS/RAF/MEK/ERK, PI3K/AKT) and can induce ADCC against EGFR-expressing tumor cells.
Cetuximab is a chimeric IgG1 monoclonal antibody against EGFR that binds the receptor’s extracellular domain, blocking ligand binding and receptor dimerization/activation, thereby inhibiting downstream RAS/RAF/MEK/ERK and PI3K/AKT signaling to suppress tumor cell proliferation; its Fc region can also mediate antibody-dependent cellular cytotoxicity (ADCC) against EGFR-expressing cells.
Cetuximab binds EGFR on target cells and its IgG1 Fc engages Fcγ receptor–bearing immune cells (e.g., NK cells) to mediate ADCC (and some CDC), resulting in lysis of EGFR-expressing cells.
Polyclonal antibody preparation that depletes T cells to reduce graft rejection and GVHD.
Polyclonal anti–T-cell immunoglobulins that bind multiple T-cell surface antigens and deplete T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and phagocytic clearance, producing immunosuppression to prevent graft rejection and GVHD.
ATG contains antibodies against CD2; binding to CD2+ cells triggers complement-dependent lysis and Fc-mediated ADCC, with additional opsonization leading to phagocytic clearance.
Polyclonal antibody preparation that depletes T cells to reduce graft rejection and GVHD.
Polyclonal anti–T-cell immunoglobulins that bind multiple T-cell surface antigens and deplete T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and phagocytic clearance, producing immunosuppression to prevent graft rejection and GVHD.
ATG antibodies bind CD3 on T cells, opsonizing them and inducing complement-dependent cytotoxicity, Fc-mediated ADCC, and phagocytic clearance, depleting CD3+ cells.
Polyclonal antibody preparation that depletes T cells to reduce graft rejection and GVHD.
Polyclonal anti–T-cell immunoglobulins that bind multiple T-cell surface antigens and deplete T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and phagocytic clearance, producing immunosuppression to prevent graft rejection and GVHD.
ATG antibodies bind CD4 on T cells and trigger complement-dependent lysis and Fc-mediated ADCC/phagocytic clearance, depleting CD4+ cells.
Polyclonal antibody preparation that depletes T cells to reduce graft rejection and GVHD.
Polyclonal anti–T-cell immunoglobulins that bind multiple T-cell surface antigens and deplete T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and phagocytic clearance, producing immunosuppression to prevent graft rejection and GVHD.
ATG binds CD5 (among other T‑cell antigens) and induces complement-dependent cytotoxicity, Fc-mediated ADCC, and opsonization leading to phagocytic clearance of CD5+ cells.